Artiva Biotherapeutics, Inc. (ARTV) stock
ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.86−0.10 (-2.53%)
Close on Nov 17, 2026Market cap $188.72MP/E –Yield –
Artiva Biotherapeutics cash
Cash and short-term investments held at the end of each period.
Artiva Biotherapeutics's cash was $349.40M at Jun 30, 2026. For fiscal 2025 it was $108.00M, down 41.7% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $108.00M | -41.7% |
| FY2024 | Dec 31, 2024 | $185.40M | +140.1% |
| FY2023 | Dec 31, 2023 | $77.23M | -24.9% |
| FY2022 | Dec 31, 2022 | $102.78M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $349.40M | +145.4% |
| Q1 FY2026 | Mar 31, 2026 | $86.80M | -47.7% |
| Q4 FY2025 | Dec 31, 2025 | $108.00M | -41.7% |
| Q3 FY2025 | Sep 30, 2025 | $123.00M | -38.4% |
| Q2 FY2025 | Jun 30, 2025 | $142.40M | +205.9% |
| Q1 FY2025 | Mar 31, 2025 | $166.00M | +244.4% |
| Q4 FY2024 | Dec 31, 2024 | $185.40M | +140.1% |
| Q3 FY2024 | Sep 30, 2024 | $199.60M | +203.0% |
| Q2 FY2024 | Jun 30, 2024 | $46.56M | -13.3% |
| Q1 FY2024 | Mar 31, 2024 | $48.20M | -53.1% |
| Q4 FY2023 | Dec 31, 2023 | $77.23M | – |
| Q3 FY2023 | Sep 30, 2023 | $65.89M | – |
| Q2 FY2023 | Jun 30, 2023 | $53.70M | – |
| Q4 FY2022 | Dec 31, 2022 | $102.78M | – |
See a number that looks wrong?